ETNB vs. IMNM, OPK, CNTA, ABVX, SPRY, LQDA, PLRX, OCUL, ARQT, and ZNTL
Should you be buying 89bio stock or one of its competitors? The main competitors of 89bio include Immunome (IMNM), OPKO Health (OPK), Centessa Pharmaceuticals (CNTA), ABIVAX Société Anonyme (ABVX), ARS Pharmaceuticals (SPRY), Liquidia (LQDA), Pliant Therapeutics (PLRX), Ocular Therapeutix (OCUL), Arcutis Biotherapeutics (ARQT), and Zentalis Pharmaceuticals (ZNTL). These companies are all part of the "pharmaceutical preparations" industry.
Immunome (NASDAQ:IMNM) and 89bio (NASDAQ:ETNB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings, community ranking and analyst recommendations.
Immunome currently has a consensus target price of $30.50, suggesting a potential upside of 121.98%. 89bio has a consensus target price of $28.14, suggesting a potential upside of 214.80%. Given Immunome's higher probable upside, analysts plainly believe 89bio is more favorable than Immunome.
89bio received 75 more outperform votes than Immunome when rated by MarketBeat users. However, 68.57% of users gave Immunome an outperform vote while only 63.06% of users gave 89bio an outperform vote.
44.6% of Immunome shares are held by institutional investors. 8.6% of Immunome shares are held by insiders. Comparatively, 2.8% of 89bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Immunome had 7 more articles in the media than 89bio. MarketBeat recorded 29 mentions for Immunome and 22 mentions for 89bio. 89bio's average media sentiment score of 0.38 beat Immunome's score of -0.17 indicating that Immunome is being referred to more favorably in the media.
89bio has a net margin of 0.00% compared to 89bio's net margin of -1,829.44%. Immunome's return on equity of -34.76% beat 89bio's return on equity.
Immunome has higher revenue and earnings than 89bio. 89bio is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.
Immunome has a beta of 1.87, meaning that its stock price is 87% more volatile than the S&P 500. Comparatively, 89bio has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500.
Summary
Immunome beats 89bio on 12 of the 17 factors compared between the two stocks.
Get 89bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ETNB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ETNB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
